Peptide News Digest

#Chinese-Biotech

3 stories

Clinical Trials · View digest

The Lancet Diabetes & Endocrinology Published Saturday August 22, 2026 the Full EECOH-2 Phase 3 Trial Results for Xianweida's Ecnoglutide (XW003), a First-in-Class cAMP-Biased GLP-1 Receptor Agonist That Preferentially Activates the cAMP Signaling Pathway Over β-Arrestin Recruitment; The 52-Week Open-Label Non-Inferiority Trial Across 52 Chinese Hospitals Compared Ecnoglutide (0.6 mg or 1.2 mg Once Weekly Subcutaneous Injection) Against Dulaglutide 1.5 mg in Adults With Type 2 Diabetes and Elevated Glucose Concentrations on Metformin Monotherapy; Both Ecnoglutide Doses Met the Non-Inferiority Endpoint on HbA1c Reduction, and Both Were Well Tolerated; The Biased-Agonism Concept (Selective Signaling Pathway Activation Rather Than Full Receptor Engagement) Has the Potential to Separate Efficacy From Side Effects in the GLP-1 Class

The Lancet Diabetes & Endocrinology published Saturday August 22, 2026 the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003), a first-in-class cAMP-biased GLP-1 receptor agonist. Mechanism: ecnoglutide preferentially activates the cAMP intracellular signaling pathway over β-arrestin recruitment when it binds the GLP-1 receptor. This biased-agonism concept selects one downstream signaling arm over the other, with the theoretical potential to separate the therapeutic effects (glucose lowering via cAMP-mediated insulin secretion) from the side-effect burden (some of which may be β-arrestin-mediated). Trial design: 52-week open-label non-inferiority Phase 3 across 52 Chinese hospitals. Adults aged 18-75 years with BMI 20-35 kg/m2, type 2 diabetes diagnosis, and elevated glucose concentrations on metformin monotherapy. Randomized to subcutaneous ecnoglutide 0.6 mg or 1.2 mg once weekly, or dulaglutide 1.5 mg once weekly (active comparator). Primary results: both ecnoglutide doses met the non-inferiority endpoint on HbA1c reduction versus dulaglutide 1.5 mg. Both doses were well tolerated with a safety profile broadly consistent with the GLP-1 receptor agonist class. Ecnoglutide is the first global cAMP-biased GLP-1 receptor agonist to reach Phase 3 publication. The biased-agonism approach could inform next-generation GLP-1 drug design and offers a differentiated tolerability profile if the concept holds in larger populations.

Industry · View digest

Chinese Biotech Peptide Pipeline Expanded Across the Week With Gan & Lee Pharmaceuticals Initiating a Phase II Clinical Trial of GZR102 (a Basal Insulin/GLP-1RA Fixed-Dose Weekly Formulation) on August 8, 2026 and Registering a Phase I Study of GZR18 on August 15; Xianweida Registered XW003 (Ecnoglutide) Phase I Clinical Trial for Adolescent Obesity on August 8; Wayne Biotech WBD156 Capsule Advanced Through Development; Fujian Genorup Semaglutide Pipeline Expanded; The Week's Pattern Extends the Chinese Biotech GLP-1 Ambition That Now Spans Ribupatide (Hengrui-Kailera, Global Phase 3 H1 2027), Mazdutide (Innovent, GLP-1/Glucagon Dual Agonist in Late-Stage Trials), MWN105 (Minwei Bio, Semaglutide-Intolerant Population), and IBI3032 (Innovent, FDA IND August 5)

Chinese biotech peptide pipeline expanded across the week ending August 22, 2026. Key registrations and advances: Gan & Lee Pharmaceuticals initiated a Phase II clinical trial of GZR102 (a basal insulin plus GLP-1 receptor agonist fixed-dose weekly formulation) on August 8, targeting patients requiring both basal glycemic control and appetite-and-glucose modulation from a single weekly injection; Gan & Lee also registered a Phase I study of GZR18 on August 15. Xianweida registered XW003 (ecnoglutide) Phase I clinical trial for adolescent obesity on August 8, extending the ecnoglutide franchise into pediatric obesity development after the adult Phase 3 EECOH-2 win. Wayne Biotech WBD156 capsule (oral peptide candidate) advanced through preclinical/early-clinical development. Fujian Genorup's semaglutide pipeline expanded across multiple formulation and indication programs. The week's pattern extends the broader Chinese biotech GLP-1 pipeline expansion that now spans ribupatide (Hengrui-Kailera, once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), mazdutide (Innovent, GLP-1/glucagon dual agonist in late-stage Chinese and US trials), MWN105 (Minwei Bio, targeting semaglutide-intolerant populations), IBI3032 (Innovent, FDA IND clearance August 5), and multiple additional candidates. The synchronized China+US development pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches.

Clinical Trials · View digest

Chinese Biotech GLP-1 Pipeline Activity Added Depth Across the Week With Minwei Bio's MWN105 Phase Ib Clinical Trial Registration (CTR20253330, Targeting Semaglutide-Intolerant Populations) and Phase II Registration (CTR20253336, Covering Non-Diabetic Overweight and Obese Patients With BMI ≥30 or BMI 27-30 With Comorbidities) on August 19-20, Plus Innovent Biologics IBI3032 FDA IND Clearance August 5 and Chinese CTR Re-Registration August 22 (CTR20253396) as Synchronized Dual-Region Clinical Development Activity Across China and the US Extending the Growing Chinese Biotech GLP-1 Pipeline That Already Includes Hengrui-Kailera's Ribupatide (Global Phase 3 H1 2027), Innovent's Mazdutide, and Multiple Other Programs Positioning to Compete With Novo Nordisk and Eli Lilly in Global Obesity Markets

Chinese biotech GLP-1 pipeline activity added depth across the week. Minwei Bio's MWN105 registered two clinical trials on August 19-20, 2026: Phase Ib (CTR20253330) targeting semaglutide-intolerant populations (patients unable to reach target Wegovy or Ozempic doses due to GI side effects, roughly 5-10% of real-world users), and Phase II (CTR20253336) covering non-diabetic overweight and obese patients (BMI ≥30 or BMI 27-30 with weight-related comorbidities). Innovent Biologics IBI3032 received FDA IND clearance August 5, 2026 for a US Phase 1 study, and on August 22 a Chinese CTR registration (CTR20253396) was activated for synchronized dual-region development. The Chinese biotech GLP-1 pipeline continues to expand across multiple programs including Hengrui-Kailera's ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), Innovent's mazdutide (GLP-1/glucagon dual agonist in late-stage Chinese and US trials), and multiple novel candidates targeting differentiated patient populations. The semaglutide-intolerant population is a real gap in the current commercial landscape: patients who cannot tolerate GI side effects at 1.7 mg or 2.4 mg semaglutide often plateau at sub-therapeutic doses. A drug specifically designed for that population would address an under-served segment. The dual-region synchronized development pattern (China IND filings + US CTR / FDA IND filings in parallel) reflects Chinese biotechs' increasing sophistication at multi-market clinical strategy.